Shares of Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) moved higher today. Print E-mail
By Staff and Wire Reports   
Monday, 28 March 2011 19:02

Below is a look at some of the headlines for companies that made news in the healthcare sector on March 28, 2011.  
Shares of Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) moved higher today after the company announced that two abstracts on KRX-0401 (perifosine) will be presented at the upcoming 102nd annual meeting of the American Association for Cancer Research (AACR) to be held in Orlando, Florida, from April 2-6, 2011. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma. Both of these Phase 3 programs are being conducted under Special Protocol Assessment agreements with the FDA, and with Fast Track designations obtained for both indications. Perifosine is also in Phase 1 and 2 clinical development for several other tumor types.
 
 
Adeona Pharmaceuticals, Inc. (AMEX:AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that the ongoing clinical trial of its Trimesta (oral estriol) drug candidate has received an additional $409,426 in grant funding from the National Multiple Sclerosis Society (NMSS). The clinical trial is led by, Rhonda Voskuhl, M.D., Director, University of California Los Angeles (UCLA) Multiple Sclerosis Program, UCLA Department of Neurology. Adeona also announced that as of March 1, 2011, the clinical trial evaluating the reduction in the rate of relapses in female multiple sclerosis (MS) patients is 85% enrolled.
 
Redwood City-based A.P. Pharma (NASDAQ:APPA) said it is also in negotiations for a bridge loan to fund operations until additional longer-term financing is secured.  Acting CEO John Whelan also said the company is working to address issues raised by the Food and Drug Administration's rejection of its recent New Drug Application. "Company representatives met with the FDA in February and have another meeting scheduled for this week," Whelan said in a prepared statement. "We believe that our discussions with the FDA will provide the necessary clarity for what work and information will be needed to best address the topics outlined in the Complete Response Letter. Following our meetings with the FDA, we expect to be in a position to determine the resources and timeline needed for resubmitting the APF530 New Drug Application."

A.P. Pharma's lead product, APF530, is designed to prevent chemotherapy-induced nausea and vomiting.  The company reported a fourth quarter loss of $1.6 million, or 4 cents a share, compared to a loss of $1.9 million, or 4 cents a share in the year-ago quarter.  Net loss for the fiscal year 2010 was $7.3 million, or 19 cents a share, compared with a loss of $10 million, or 31 cents a share for 2009.

 
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) and MolecularMD Corporation today announced an exclusive collaboration agreement in which MolecularMD will develop and commercialize a companion diagnostic test to identify the T315I mutation of the BCR-ABL gene in patients with chronic myeloid leukemia (CML) and Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL).
 


Also Monday:

Cardio Infrared Technologies, Inc. (PINKSHEETS:CDOI) www.cardio-cor.com, www.thebiofit.com, a leading Health and Wellness technology and marketing company, announced today the first of the new generation infrared bike was installed in Utah in November 2010.

D. Medical Industries Ltd. (NASDAQ:DMED) (TASE:DMED) ("D. Medical" or the "Company"), a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery, announced today that its subcontractor, UPG (Suzhou) EPZ Co. Ltd. ("UPG"), a subsidiary of United Plastics Group, Inc., has commenced the mass production of its Spring Universal Infusion Sets in Suzhou, China.

Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that one-year clinical outcomes from Cohort A of The PARTNER Trial are scheduled to be presented at 9:15 a.m. CT on Sunday, April 3, at the American College of Cardiology's (ACC) 60th Annual Scientific Session & Expo in New Orleans, La.

eHealthInsurance (NASDAQ: EHTH), the leading online source of health insurance for individuals and families, today released a series of consumer tips to help 2011 college grads navigate their health insurance opportunities and make an informed coverage decision.

GenSpera, Inc. (OTCBB:GNSZ) announced that the first patient was dosed in the ongoing Phase I clinical study of its chemotherapeutic agent, G-202, at the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio in San Antonio, Texas.

Healthnostics, Inc. (PINKSHEETS: HNSS) announced that U.S. News Company has increased its offer to purchase 10 million shares of HNSS common stock to $.0115 per share after no stockholders availed themselves of the previous $.01 per share offer.

MMRGlobal, Inc. (OTCBB: MMRF) today announced it will host a Fourth Quarter and Year-End 2010 Earnings conference call on Thursday, March 31, 2011, at 2:00 p.m. Pacific Time/5:00 p.m. Eastern Time.

Rural/Metro Corporation (NASDAQ: RURL) (the "Company"), a leading national provider of ambulance and private fire protection services, today announced it has entered into a definitive agreement for the acquisition of the Company by the private equity firm Warburg Pincus in an all-cash transaction.

Syneron Medical Ltd. (NASDAQ: ELOS), http://www.syneron.com, the leading global aesthetic device company, today announced that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2010, as filed with the Securities and Exchange Commission on March 28, 2011, is available through its website (http://www.syneron.com).

The Tecan Group (SWISS: TECN) and HP (NYSE: HPQ) today announced that they have entered into an agreement to commercialize products based on HP's high-performance inkjet dispensing technology for pharmaceutical drug discovery.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter